alexa Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders.
Molecular Biology

Molecular Biology

Journal of Cell Science & Therapy

Author(s): Goodman M

Abstract Share this page

Abstract Autoimmune rheumatologic disease has a wide range of clinical expression that occasionally can be disabling. Patients with visceral organ involvement are exposed to significant morbidity and mortality if effective therapy is not forthcoming. The mainstay of therapy has been immunosuppression. However, some patients fail to respond to conventional doses of corticosteroids, methotrexate, or cyclophosphamide, and new approaches are needed for these patients. One new approach involves the use of intensified immunosuppression by combining cyclophosphamide with purine nucleoside analogs, including the adenosine deaminase inhibitor pentostatin (Nipent; SuperGen, San Ramon, CA).
This article was published in Semin Oncol and referenced in Journal of Cell Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version